Actuate Therapeutics Inc (ACTU) Financial Ratios
4 years of historical data (2022–2025) · Healthcare · Biotechnology
EV/EBITDA
N/A
—
5yr avg: N/A
P/FCF
N/A
—
5yr avg: N/A
P/B Ratio
↓
5.36
↓-99% vs avg
5yr avg: 753.58
30Y Low16.2·High16.2
ROE
↓
-553.7%
↓+94% vs avg
5yr avg: -8959.6%
30Y Low-136%·High-136%
Debt/EBITDA
N/A
—
5yr avg: N/A
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
ACTU Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Actuate Therapeutics Inc currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
| Market Cap | $48M | $129M | $155M | — | — |
| Enterprise Value | $36M | $116M | $147M | — | — |
| P/E Ratio → | -1.91 | — | — | — | — |
| P/S Ratio | — | — | — | — | — |
| P/B Ratio | 5.36 | 16.24 | 1490.92 | — | — |
| P/FCF | — | — | — | — | — |
| P/OCF | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
ACTU EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
| EV / Revenue | — | — | — | — | — |
| EV / EBITDA | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — |
| EV / FCF | — | — | — | — | — |
ACTU Profitability
Margins and return-on-capital ratios measuring operating efficiency
A negative ROE of -553.7% indicates the company is currently destroying shareholder equity.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
| Gross Margin | — | — | — | — | — |
| Operating Margin | — | — | — | — | — |
| Net Profit Margin | — | — | — | — | — |
Return on Capital
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
| ROE | -553.7% | -553.7% | -26189.1% | — | -135.9% |
| ROA | -190.4% | -190.4% | -443.2% | -210.8% | -98.4% |
| ROIC | — | — | — | — | — |
| ROCE | -508.7% | -508.7% | -4876.6% | -409.0% | -125.2% |
ACTU Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
The company holds a net cash position — cash of $13M exceeds total debt of $404991, providing substantial financial flexibility for buybacks, acquisitions, or weathering downturns.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
| Debt / Equity | 0.05 | 0.05 | — | — | 0.03 |
| Debt / EBITDA | — | — | — | — | — |
| Net Debt / Equity | — | -1.61 | -82.94 | — | -1.35 |
| Net Debt / EBITDA | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — |
| Interest Coverage | -1110.84 | -1110.84 | -1458.78 | -566.00 | -1243.41 |
Net cash position: cash ($13M) exceeds total debt ($404991)
ACTU Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
Actuate Therapeutics Inc's current ratio of 2.39x is well above the 1.0 safety threshold, indicating strong short-term liquidity with ample room to cover current liabilities. The current ratio has improved from 0.43x to 2.39x over the past 3 years.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
| Current Ratio | 2.39 | 2.39 | 1.05 | 0.43 | 4.71 |
| Quick Ratio | 2.39 | 2.39 | 1.05 | 0.43 | 4.71 |
| Cash Ratio | 2.31 | 2.31 | 0.98 | 0.43 | 4.71 |
| Asset Turnover | — | — | — | — | — |
| Inventory Turnover | — | — | — | — | — |
| Days Sales Outstanding | — | — | — | — | — |
ACTU Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Actuate Therapeutics Inc does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — |
| FCF Yield | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | — | — |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | — | — |
| Shares Outstanding | — | $21M | $20M | $15M | $15M |
Peer Comparison
Compare ACTU with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 ACTUYou | $48M | -1.9 | — | — | — | — | -553.7% | — | — |
 IMVT | $7B | -12.1 | — | — | — | — | -64.8% | — | — |
 TPVG | $226M | 4.6 | 8.9 | — | 83.5% | 77.9% | 14.1% | 7.2% | 6.2 |
 AGIO | $2B | -4.1 | — | — | 78.7% | -873.9% | -30.2% | -26.3% | — |
 PRAX | $8B | -19.8 | — | — | — | — | -45.8% | -65.0% | — |
 IDYA | $3B | -22.6 | — | — | 97.9% | -72.8% | -10.9% | -12.4% | — |
 MGNX | $252M | -3.4 | — | — | 71.1% | -48.7% | -86.9% | -144.1% | — |
 NKTR | $1B | -6.1 | — | — | 100.0% | -236.8% | -217.9% | -57.2% | — |
 CRVS | $1B | -22.5 | — | — | — | — | -32.6% | -78.1% | — |
 ALDX | $106M | -3.1 | — | — | — | — | -58.7% | -245.8% | — |
 CRL | $9B | -64.4 | 13.0 | 17.4 | 30.5% | 12.6% | -4.3% | 6.3% | 3.4 |
| Healthcare Median | — | 22.9 | 14.4 | 18.9 | 63.9% | -4.3% | -32.6% | -11.4% | 3.2 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 4 years · Updated daily
What if you invested $1,000 in ACTU 10 years ago?
Total return calculator · dividends reinvested
Calculate ReturnsHow much would $100/month in ACTU be worth today?
Dollar cost averaging vs lump sum · see how regular investing compounds over time
Run the NumbersIs ACTU Undervalued Right Now?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationACTU vs IMVT — which is the better buy?
Side-by-side revenue, margins, P/E and 10-year returns vs Immunovant, Inc..
Compare NowACTU — Frequently Asked Questions
Quick answers to the most common questions about buying ACTU stock.
What is Actuate Therapeutics Inc's P/E ratio?
Actuate Therapeutics Inc's current P/E ratio is -1.9x. This places it at the 50th percentile of its historical range.
What is Actuate Therapeutics Inc's ROE?
Actuate Therapeutics Inc's return on equity (ROE) is -553.7%. The historical average is -135.9%.
Is ACTU stock overvalued?
Based on historical data, Actuate Therapeutics Inc is trading at a P/E of -1.9x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.